Sequent Scientific Limited (SEQUENT.NS)

INR 180.0

(-1.51%)

Market Cap (In INR)

45.05 Billion

Revenue (In INR)

13.69 Billion

Net Income (In INR)

-358.69 Million

Avg. Volume

3.16 Million

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
92.05-240.7
PE
-
EPS
-
Beta Value
0.816
ISIN
INE807F01027
CUSIP
Y7670U126
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Rajaram Narayanan
Employee Count
-
Website
https://www.sequent.in
Ipo Date
2016-03-10
Details
Sequent Scientific Limited engages in the animal health business worldwide. The company provides animal health active pharmaceutical ingredients (APIs) and finished dosage formulations in the areas of feed supplements, antibiotics, anthelmintics, antibacterial, anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It offers analytical solutions that supports API, pharmaceutical, personal care, and nutraceutical organizations, as well as provides method validation, stability, and microbiology for APIs and finished products. The company was formerly known as PI Drugs and Pharmaceuticals Limited and changed its name to Sequent Scientific Limited in October 2009. Sequent Scientific Limited was incorporated in 1985 and is headquartered in Mumbai, India. Sequent Scientific Limited operates as a subsidiary of CA Harbor Investments.